Effectively Integrating a Regionally Specialized CRO Team into Your Existing US/Global Study Framework
The expansion of an oncology study to ex-US areas, such as Canada, brings many advantages, including faster patient accrual and…
Key Attributes of First-In-Class Oncology Clinical Trial Sponsors
Key Attributes of First-In-Class Oncology Clinical Trial Sponsors Overcoming Current Industry Challenges through Excellence Current industry trends that increasingly contribute…
Navigating Canadian Regulations for Oncology Clinical Research – Part II
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part II Senior executives from oncology drug developers looking to…
Navigating Canadian Regulations for Oncology Clinical Research – Part I
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part I Senior executives from oncology drug developers looking to…
The Nearshoring Opportunity: Building a Solid Case for Oncology Studies in Canada
US Sponsors of oncology clinical trials often consider expanding their programs to Europe and Asia rather than to the nearby…
Julie’s advice: Conducting oncology clinical research in Canada
Julie's advice: Conducting oncology clinical research in Canada Include Canada early in your drug development planning! Building relationships with key…
Clinical Trial Agreements no longer a bottleneck for study site activation
Ending the clinical trial agreement's sabotage of clinical trial startup Clinical trials are inherently complex, from pre-study startup through to…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
Continued from ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiation part 1 Nathan Currier, PhD, is Scimega's…
Oncology Clinical Operations in Canada
The nature and structure of our health care system in Canada results in patients being followed at the same center…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
Nathan Currier, PhD, is Scimega's Director of Oncology Strategy and Alliances. He brings a wealth of knowledge and excellent insight…